Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Yamo Deniz"'
Autor:
Wytske J Fokkens, Claus Bachert, Claire Hopkins, Osama Marglani, Amy Praestgaard, Scott Nash, Yamo Deniz, Paul J Rowe, Harry Sacks, Juby A Jacob‐Nara
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Objectives This post hoc analysis assessed disease characteristics and response to dupilumab treatment in male and female patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (SINUS‐52 study; NCT02898454). Methods Patient
Externí odkaz:
https://doaj.org/article/cfa966c8d76542fe808ba1868727c8f7
Autor:
Christian Domingo, Klaus F. Rabe, David Price, Guy Brusselle, Michael E. Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Paul J. Rowe, Yamo Deniz, Juby A. Jacob-Nara, Amr Radwan
Publikováno v:
ERJ Open Research, Vol 9, Iss 6 (2023)
Background Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg
Externí odkaz:
https://doaj.org/article/4cc17fdbebce48e9b57861c1623c47cb
Autor:
Jonathan Corren, Constance H. Katelaris, Mario Castro, Jorge F. Maspero, Marc Humbert, David M.G. Halpin, Arman Altincatal, Nami Pandit-Abid, Xavier Soler, Amr Radwan, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe
Publikováno v:
ERJ Open Research, Vol 9, Iss 5 (2023)
Background The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients
Externí odkaz:
https://doaj.org/article/5dd99f3023aa41019700fab408bfb6d4
Autor:
Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Jerome Msihid, Michel Djandji, Benjamin Ortiz, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Masato Ishida, Kazuhiko Arima
Publikováno v:
Allergology International, Vol 72, Iss 1, Pp 89-99 (2023)
Background: Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma. Methods: The TRAVERSE open-label extension (OLE) study (NCT02134028) assessed the safety and efficacy of dupilumab 30
Externí odkaz:
https://doaj.org/article/a6454e7b2c504233a7b1ee0de552fd38
Autor:
Mirna Chehade, Gary W. Falk, Seema Aceves, Jason K. Lee, Vinay Mehta, John Leung, Brad Shumel, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Danen Cunoosamy, Angela Khodzhayev
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 5, Pp 720-732 (2022)
Eosinophilic esophagitis (EoE) is a chronic type 2 inflammatory disease characterized by an eosinophilic inflammatory infiltrate in the esophagus, leading to remodeling, stricture formation, and fibrosis. Triggered by food and aeroallergens, type 2 c
Externí odkaz:
https://doaj.org/article/bc974838088c4751b97ca2480fc9086f
Autor:
Eugene R. Bleecker, Reynold A. Panettieri, Njira L. Lugogo, Jonathan Corren, Nadia Daizadeh, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Angela Khodzhayev, Xavier Soler, Thomas J. Ferro, Christopher N. Hansen
Publikováno v:
Journal of Immunology Research, Vol 2023 (2023)
Introduction. Elevated neutrophil counts in blood, sputum, or lung have been associated with poor clinical outcomes and more severe disease in patients with type 2 asthma. In the phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add-on dupilumab 200 and 30
Externí odkaz:
https://doaj.org/article/8706189fb30a4dbaa47f559ad5ce61fe
Autor:
Shahid Siddiqui, Claus Bachert, Adam M. Chaker, Joseph K. Han, Peter W. Hellings, Anju T. Peters, Enrico Heffler, Siddhesh Kamat, Haixin Zhang, Scott Nash, Asif H. Khan, Lucia De Prado Gomez, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nasal and paranasal sinuses. Dupilumab is a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, wh
Externí odkaz:
https://doaj.org/article/bd6ab2fceb3e47b39463130f9fec492b
Autor:
Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Kazuhiko Arima, Masanori Miyata, Yoshinori Takahashi, Megan S. Rice, Yamo Deniz, Paul Rowe, Naimish Patel, Neil M.H. Graham, Ariel Teper
Publikováno v:
Allergology International, Vol 69, Iss 4, Pp 578-587 (2020)
Background: In the LIBERTY ASTHMA QUEST (ClinicalTrials.gov: NCT02414854) study, dupilumab 200 mg and 300 mg every 2 weeks vs matched-volume placebo reduced severe asthma exacerbations and improved lung function (FEV1), asthma control, and quality of
Externí odkaz:
https://doaj.org/article/9cdc2eefd38c43cabfa8ef718643133b
Autor:
Lawrence D. Sher, Jonathan Corren, Ian D. Pavord, Nadia Daizadeh, Arman Altincatal, Xavier Soler, Michel Djandji, Amr Radwan, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe
Publikováno v:
Journal of Asthma. :1-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3c2ea9984bb36fef1817020b65c5069
https://doi.org/10.1080/02770903.2023.2185895
https://doi.org/10.1080/02770903.2023.2185895
Autor:
Jonathan Corren, David J Jackson, Thomas B Casale, Larry Borish, Klaus F Rabe, William W Busse, Jorge F Maspero, Daniel J Jackson, Nadia Daizadeh, Arman Altincatal, Amr Radwan, Angela Khodzhayev, Michel Djandji, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz
Publikováno v:
Journal of Asthma and Allergy. 16:249-260
Jonathan Corren,1 David J Jackson,2,3 Thomas B Casale,4 Larry Borish,5,6 Klaus F Rabe,7,8 William W Busse,9 Jorge F Maspero,10 Daniel J Jackson,11 Nadia Daizadeh,12 Arman Altincatal,12 Amr Radwan,13 Angela Khodzhayev,13 Michel Djandji,12 Juby A Jacob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26cce8f6a91ef3d5661404c0c4476095
https://doi.org/10.2147/jaa.s385645
https://doi.org/10.2147/jaa.s385645